SCHEMBL4568709

SCHEMBL4568709

C#CC(O)(c1ccc(C)cc1)c1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.54
RELA Q04206 1/20 0.44
NPC1 O15118 4/20 0.42
RAB9A P51151 3/20 0.42
ELANE P08246 1/20 0.41
KIF11 P52732 2/20 0.41
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 2/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
AOC3 Q16853 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25954061 0.93 ELANE (0.46) ACHEELANECA12CA1CA2
SCHEMBL164160 0.93 ELANE (0.46) ACHEELANECA12CA1CA2
SCHEMBL25954054 0.91 RELA (0.62) ACHERELANPC1RAB9ASMN1; SMN2
SCHEMBL25954108 0.87 LTA4H (0.48) NPC1RAB9AELANECA12CA1
SCHEMBL25954134 0.87 ELANE (0.42) ACHENPC1RAB9AELANECA12
SCHEMBL25954105 0.87 ESR2 (0.48) NPC1RAB9AELANECA12CA1
SCHEMBL25954058 0.87 LTA4H (0.48) NPC1RAB9AELANECA12CA1
SCHEMBL25954129 0.87 TEAD4 (0.44) ACHENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL8782519 0.87 TSHR (0.44) ACHENPC1RAB9ACA1CA2
SCHEMBL1011203 0.86 KIF11 (0.45) ELANEKIF11SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023140186-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES 株式会社トクヤマ 2023-07-27 WO disclosed
WO-2023136213-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES 株式会社トクヤマ 2023-07-20 WO disclosed
US-9643905-B2 Phenylnaphthol derivatives TOKUYAMA CORPORATION (JP) 2017-05-09 US disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
US-20160130203-A1 NOVEL PHENYLNAPHTHOL DERIVATIVES TOKUYAMA CORPORATION (JP) 2016-05-12 US disclosed
US-20150034887-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2015-02-05 US disclosed
US-20150034887-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2015-02-05 US disclosed
US-8916071-B2 Chromene compound and curable composition TOKUYAMA CORPORATION (JP) 2014-12-23 US disclosed
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2014-08-14 US disclosed
US-20120121934-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-05-17 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-8123987-B2 Chromene compounds TOKUYAMA CORPORATION (JP) 2012-02-28 US disclosed
US-8123987-B2 Chromene compounds TOKUYAMA CORPORATION (JP) 2012-02-28 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
US-20100230648-A1 Chromene Compounds TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed
US-20100230648-A1 Chromene Compounds TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed
EP-1978022-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2008-10-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130203-A1 NOVEL PHENYLNAPHTHOL DERIVATIVES AHR, ARL1, PAH ACHE 3663/4885RELA 1546/4885NPC1 2951/4885
US-20100230648-A1 Chromene Compounds H1-4, RB1, H1-0 ACHE 2565/4885RELA 1644/4885NPC1 3522/4885
US-20150034887-A1 CHROMENE COMPOUND CRY2, TRMT1, CDK20 ACHE 1859/4885RELA 4102/4885NPC1 3167/4885
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION CRY2, CRY1, CDYL ACHE 2034/4885RELA 1916/4885NPC1 4022/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 ACHE 2579/4885RELA 2673/4885NPC1 809/4885
US-20120121934-A1 CHROMENE COMPOUND TST, CNOT1, CNOT9 ACHE 2105/4885RELA 4169/4885NPC1 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.